Scalper1 News
Molecular diagnostic company Cepheid (CPHD) late Thursday reported a narrower-than-expected Q3 loss and issued Q4 guidance that beat Wall Street views, which sent its shares rising Friday. Cepheid stock was up more than 5% in afternoon trading in the stock market today, near 47. The Sunnyvale, Calif.-based company said it expects revenue of $122 million to $126 million in the current quarter, with earnings per share ex-items of 2 cents to 4 cents. Scalper1 News
Scalper1 News